{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:07:31Z","timestamp":1788404851291,"version":"build-2803163510"},"reference-count":107,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,8,17]]},"abstract":"<jats:p>Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.<\/jats:p>","DOI":"10.1128\/aac.01043-21","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T19:27:30Z","timestamp":1625599650000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile"],"prefix":"10.1128","volume":"65","author":[{"given":"Vianney","family":"Tuloup","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France"},{"name":"Universit\u00e9 Lyon, Universit\u00e9 Lyon 1, UMR CNRS 5558, Laboratoire de Biom\u00e9trie et Biologie Evolutive, Villeurbanne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"France","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Garreau","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France"},{"name":"Universit\u00e9 Lyon, Universit\u00e9 Lyon 1, UMR CNRS 5558, Laboratoire de Biom\u00e9trie et Biologie Evolutive, Villeurbanne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bleyzac","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bourguignon","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France"},{"name":"Universit\u00e9 Lyon, Universit\u00e9 Lyon 1, UMR CNRS 5558, Laboratoire de Biom\u00e9trie et Biologie Evolutive, Villeurbanne, France"},{"name":"Universit\u00e9 Lyon, Universit\u00e9 Lyon 1, ISPB, Facult\u00e9 de Pharmacie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tod","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France"},{"name":"Universit\u00e9 Lyon, Universit\u00e9 Lyon 1, UMR CNRS 5558, Laboratoire de Biom\u00e9trie et Biologie Evolutive, Villeurbanne, France"},{"name":"Universit\u00e9 Lyon, Universit\u00e9 Lyon 1, ISPB, Facult\u00e9 de Pharmacie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-2932","authenticated-orcid":true,"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie, Lyon, France"},{"name":"Universit\u00e9 Lyon, Universit\u00e9 Lyon 1, UMR CNRS 5558, Laboratoire de Biom\u00e9trie et Biologie Evolutive, Villeurbanne, France"},{"name":"Universit\u00e9 Lyon, Universit\u00e9 Lyon 1, ISPB, Facult\u00e9 de Pharmacie de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw024"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0068"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(94)90079-5"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00959-19"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa401"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa403"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa061"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69228-z"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31814a586a"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.747952"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00615223"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1073"},{"key":"e_1_3_3_15_2","unstructured":"DDI-Predictor. 2021. Quantitative prediction of drug drug interactions\u2014DDI-Predictor academic version. https:\/\/www.ddi-predictor.org\/."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9431-9"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0031-3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/11592620-000000000-00000"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0371-x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.4155\/ipk.16.2"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9663-y"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1918"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.06.021"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-199912000-00007"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.125"},{"key":"e_1_3_3_26_2","first-page":"387","article-title":"Comparative effects of rifampin and\/or probenecid on the pharmacokinetics of temazepam and nitrazepam","volume":"28","author":"Brockmeyer NH","year":"1990","unstructured":"Brockmeyer NH, Mertins L, Klimek K, Goos M, Ohnhaus EE. 1990. Comparative effects of rifampin and\/or probenecid on the pharmacokinetics of temazepam and nitrazepam. Int J Clin Pharmacol Ther Toxicol 28:387\u2013393.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12448"},{"key":"e_1_3_3_28_2","unstructured":"European Medicines Agency. 2018. Emend. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emend."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.04.007"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0068-3"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku171"},{"key":"e_1_3_3_32_2","unstructured":"European Medicines Agency. 2018. Rxulti. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rxulti."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.723"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.04.013"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1999.tb00880.x"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.510"},{"key":"e_1_3_3_37_2","unstructured":"ASHP. 2020. Carbamazepine. Monograph for professionals. https:\/\/www.drugs.com\/monograph\/carbamazepine.html."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009353761"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi.2003.19.4.287"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S249098"},{"key":"e_1_3_3_41_2","unstructured":"emc. 2018. Mycobutin\u2014SmPC. (Summary of patient characteristics.) https:\/\/www.medicines.org.uk\/emc\/product\/1088\/smpc."},{"key":"e_1_3_3_42_2","unstructured":"European Medicines Agency. 2018. Xalkori. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xalkori."},{"key":"e_1_3_3_43_2","unstructured":"European Medicines Agency. 2018. Daklinza. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/daklinza."},{"key":"e_1_3_3_44_2","unstructured":"European Medicines Agency. 2018. Sprycel. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sprycel."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.01.010"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb00535.x"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0497-3"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2390-3"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14302"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70138-4"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt421"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0648-1"},{"key":"e_1_3_3_53_2","unstructured":"European Medicines Agency. 2018. Flibanserin. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-000085-pip01-07."},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140040-00003"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-015-0118-4"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544100-00005"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.04.001"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.115822"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00295.x"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.156"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0722-9"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.285"},{"key":"e_1_3_3_63_2","unstructured":"European Medicines Agency. 2018. Kalydeco. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kalydeco."},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.785"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01198-9"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90163-1"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi-2014-0005"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1211\/0022357001777243"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.11.016"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90018-1"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00902-w"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.693"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746020-00001"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.084905"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215586824"},{"key":"e_1_3_3_76_2","first-page":"1121","article-title":"The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism","volume":"24","author":"Holtbecker N","year":"1996","unstructured":"Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. 1996. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121\u20131123.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010367428"},{"key":"e_1_3_3_78_2","unstructured":"ASHP. 2020. Olaparib. Monograph for professionals. https:\/\/www.drugs.com\/monograph\/olaparib.html."},{"key":"e_1_3_3_79_2","unstructured":"European Medicines Agency. 2018. Ibrance. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ibrance."},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05071.x"},{"key":"e_1_3_3_81_2","unstructured":"European Medicines Agency. 2018. Wakix. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wakix."},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.182"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.129319"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315399"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6369.923"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02218.x"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519120-00007"},{"key":"e_1_3_3_88_2","unstructured":"European Medicines Agency. 2018. Stivarga. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stivarga."},{"key":"e_1_3_3_89_2","unstructured":"European Medicines Agency. 2018. Kisqali. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kisqali."},{"key":"e_1_3_3_90_2","unstructured":"European Medicines Agency. 2018. Jakavi. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jakavi."},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01631.x"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111414"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2533-2"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.3078"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00764-x"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.507"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544090-00003"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0127-x"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.350"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90176-4"},{"key":"e_1_3_3_101_2","unstructured":"European Medicines Agency. 2018. Esmya. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/esmya."},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.2165\/11586980-000000000-00000"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0117-6"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90082-5"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00579.x"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-04015-w"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1072"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.5.8912765"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01043-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01043-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:05:17Z","timestamp":1645484717000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01043-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,8,17]]}},"alternative-id":["10.1128\/AAC.01043-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01043-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"2021-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01043-21"}}